GI bleeding: Which NOAC is lowest risk in AF?
Researchers analysed data from half a million new users of apixaban, dabigatran, edoxaban and rivaroxaban
For patients with AF, apixaban use is associated with a lower risk for gastrointestinal bleeding compared with other non-vitamin K antagonist oral anticoagulants, according to a study published in the Annals of Internal Medicine.
Dr Wallis CY Lau (PhD), from the University College London school of pharmacy, and colleagues conducted a large-scale comparison between all non-vitamin K antagonist oral anticoagulants (NOACs) in routine clinical practice in a multinational study.
